Vascular Endothelial Growth Factor Overexpression Clinical Trial
Official title:
Differential Regulation of VEGF, Cadherin and Angiopietin 2 by Trigger Oocyte Maturation With GnRHa vs hCG in Donors: Try to Explain the Lower OHSS Incidence
NCT number | NCT00848185 |
Other study ID # | IVIMAD-MC-10-2008-01 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | June 2008 |
Est. completion date | March 2009 |
Verified date | April 2018 |
Source | IVI Madrid |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Introduction OHSS still remains a complication of assisted reproduction treatments. hCG administration to trigger final oocyte maturation will release vascular mediators, being VEGF and other proteins such as VE-Cadherin or Angiopoietin- 2. It has been shown that replacing hCG by GnRH agonists will induce a very short endogenous LH peak, potent enough to induce final oocyte maturation but no OHSS will develop. The investigators examined VEGF, VE-Cadherin and Angiopoietin-2 modulation by hCG as well as GnRH agonists in oocyte donors undergoing controlled ovarian stimulation.
Status | Completed |
Enrollment | 96 |
Est. completion date | March 2009 |
Est. primary completion date | February 2009 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 34 Years |
Eligibility |
Inclusion Criteria: - Donors Exclusion Criteria: - Important diseases |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
IVI Madrid |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | VEGF Protein and mRNA Levels | VEGF concentration in follicular fluid and VEGF mRNA expression in granulosa cells from patients who received either GnRH agonist instead of hCG | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02168322 -
Perforated Barrier Membranes Maintain Physiologic Gingival Crevicular Fluid Growth Factor Levels
|
N/A | |
Terminated |
NCT04991350 -
Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema
|
Phase 4 | |
Completed |
NCT04970251 -
Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma
|
N/A | |
Completed |
NCT04674254 -
Macular Perfusion Changes After Anti-VEGF Versus Targeted Retinal Photocoagulation in Proliferative Diabetic Retinopathy
|
Phase 4 | |
Completed |
NCT02447679 -
Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence
|
Phase 2 | |
Recruiting |
NCT03648814 -
Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT
|
N/A | |
Completed |
NCT02708537 -
Effect of Plasma Rich in Growth Factors on Semen Quality
|